Últimas noticias sobre Genprex (NASDAQ:GNPX) Bolsa

Genprex

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Genprex Inc

News

Dividends

FBIZ

First Business Bank Increases Dividend From $0.25 To $0.29

Standard Chartered&#8216;s Head of Digital Assets Research Geoffrey Kendrick on Monday advised against buying the dip in cryptocurrencies until outright back-end <a href="https://www.benzinga.com/25/01/42939374/as-bond-yields-near-the-crucial-5-mark-last-seen-briefly-in-2023-and-global-financial-crisis-this-analyst-says-market-appears-to-be-overreacting">U.S. Treasury yields come lower</a>.
What Happened: In a note to Benzinga, Kendrick stated that the current sell-off differs significantly from the previous one.
While last week&#8217;s decline, driven by developments around <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43248978/could-bitcoin-see-a-deeper-dip-on-the-deepseek-ai-shock">China&#8217;s DeepSeek</a>, was a buying opportunity, today&#8217;s market downturn stems from newly imposed U.S. tariffs on Canada and Mexico, fueling inflation concerns and dragging down risk assets.
Kendrick explained that the tariffs are having a &#8220;outright negative&#8221; effect on digital asset prices by increasing U.S. inflation expectations. 
He highlighted a 10 basis point increase in 2-year inflation expectations since Friday, further compounding the pressure on risk assets.
&#8220;The bigger/next question for me is whether and/or when growth fears outweigh inflation fears,&#8221; he said, explaining that the market needs to see nominal yields at the longer end of the U.S. Treasury curve come down, which would signal growth concerns are taking precedence over inflation.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43430801/exclusive-anthony-scaramucci-warns-donald-trumps-crypto-promises-may-be-a-mirage">EXCLUSIVE: Anthony Scaramucci Warns Donald Trump&#8217;s Crypto Promises May Be A &#8216;Mirage&#8217;</a>
Why It Matters: Major cryptocurrencies have experienced <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43432142/dogecoin-shiba-inu-crater-13-as-bitcoin-takes-a-tariff-beating">dramatic price drops</a> early Monday morning.
Within the last 24 hours, top tokens have slumped by over 25%, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) down approximately 7% and Ether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) plummeting by 20% in morning trade. 
Other major tokens including Ripple&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Cardano's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) have fallen by more than 25% reversing all the gains since December. 
This sharp downturn has wiped out gains made since the start of December, reaching levels not seen since early November before the U.S. election. In fact, many major tokens have fallen between 40 and 50% in the past month alone.
The rapid decrease in price triggered significant liquidations, with total liquidations across exchanges exceeding $2.2 billion, the highest so far this year and among the most substantial in the past year. 
A single liquidation order on Binance, involving a $25 million Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>)-margined ETH trade, suggests the severity of the market downturn.
Kendrick suggests that while digital assets will eventually benefit from lower real yields and higher inflation expectations in the US treasury market, it will take lower outright nominal yields to solidify that. 
He advised that investors should wait until there are explicit signs of growth fears dominating inflation concerns. 
Until then, he believes that the market may be in for a &#8220;choppy few days where the $90,000 level in BTC is again at risk."
Kendrick warns that the current market conditions are not conducive to immediately buying the dip, given the potential for further volatility until there is evidence that growth fears are <a href="https://www.benzinga.com/news/econ-s/25/01/43396354/inflation-rises-again-may-be-end-of-the-road-for-interest-rate-cuts-expert-says">outpacing inflation fears</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43404802/grayscale-seeks-sec-approval-to-convert-xrp-trust-into-exchange-traded-fund">Grayscale Seeks SEC Approval To Convert XRP Trust Into Exchange-Traded Fund</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$BTC

$DOGE

$ETH

$USDT

$XRP

Don't Buy The Dip On Bitcoin, Ethereum, XRP Yet, Standard Chartered Warns

B. Riley Securities analyst Craig Ellis maintains GCT Semiconductor Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCTS#NYSE">GCTS</a>) with a Buy and lowers the price target from $8 to $5.

Price Target

Analyst Ratings

GCTS

B. Riley Securities Maintains Buy on GCT Semiconductor Hldgs, Lowers Price Target to $5

EYEN

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

PROC

Procaps Group Receives Nasdaq Delisting Notice

&nbsp;Shares of retail stocks are trading lower as investors evaluate U.S. tariff risks which may negatively impact industry revenues.&nbsp;
&nbsp;Shares of retail stocks are trading lower as investors evaluate U.S. tariff risks which may negatively impact industry revenues.&nbsp;

WIIM

BARK

BGFV

BURL

CANG

CVNA

DLTR

FIVE

LULU

MUSA

PLCE

REAL

SFIX

SHOO

ULTA

Shares of retail and apparel stocks are trading lower as investors evaluate U.S. tariff risks which may hinder industry sales.

Earnings

Coffee Holding FY24 EPS $0.39 Up From $(0.15) YoY; Net Sales Up 15% YoY

B. Riley Securities analyst Josh Nichols reiterates Gentex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) with a Buy and lowers the price target from $37 to $32.5.

Reiteration

GNTX

B. Riley Securities Reiterates Buy on Gentex, Lowers Price Target to $32.5

Keybanc analyst Justin Patterson upgrades Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) from Sector Weight to Overweight and announces $100 price target.

Upgrades

Keybanc Upgrades Zillow Gr to Overweight, Announces $100 Price Target

Baker Hughes Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) disclosed several transactions and partnerships at the Baker Hughes <a target="_blank" href="https://www.benzinga.com/quote/BKR" rel="noreferrer noopener">2025 Annual Meeting in Florence</a>.
ExxonMobil Contract: Baker Hughes secured a contract from Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) Guyana to supply specialty chemicals and services for the Uaru and Whiptail offshore <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43426683/baker-hughes-secures-major-chemicals-award-from-exxonmobil-guyana-for-fpsos" rel="noreferrer noopener">developments in the Stabroek Block</a>.
Uaru and Whiptail are ExxonMobil Guyana&#8217;s fifth and sixth projects, featuring up to 20 drill centers and 92 wells.
Each FPSO will have a capacity of 250,000 barrels per day, raising the country's total production capacity to 1.3 million barrels per day.
The multi-year contract covers topsides, subsea, water injection, and utility chemicals for the Errea Wittu and Jaguar FPSOs, set to begin production in 2026 and 2027, respectively.
Hanwha Partnership: Baker Hughes inked a joint Development and Collaboration Agreement (JDCA) with Hanwha Power Systems and Hanwha Ocean to develop a small-size <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43426721/baker-hughes-and-hanwha-announce-partnership-to-develop-small-size-ammonia-turbines" rel="noreferrer noopener">turbine for ammonia applications</a>.
The turbine will combine Baker Hughes&#8217; gas turbine technology with Hanwha&#8217;s ammonia combustion system.
Baker and Hanwha plan to complete full engine testing with ammonia by the end of 2027, after which the ~16MW turbine will be available for commercial orders.
Argent LNG Contract: The company has been chosen by Argent LNG as the liquefaction solution and services provider for its proposed LNG <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43427007/argent-lng-selects-baker-hughes-as-technology-provider-strengthening-project" rel="noreferrer noopener">export facility in Port Fourchon, Louisiana</a>.
Baker Hughes will supply liquefaction technology, power generation equipment, and gas compression systems for the facility, which aims to produce approximately 24 MTPA of LNG.
Last month, Baker Hughes reported fourth-quarter adjusted EPS&nbsp;of $0.70, beating the consensus of $0.63 and sales&nbsp;of $7.36 billion, exceeding <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43356061/baker-hughes-announces-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">the street view of&nbsp;$7.08 billion</a>.
Investors can gain exposure to the stock via iShares U.S. Oil Equipment &amp; Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEZ#NYSE">IEZ</a>) and&nbsp;VanEck Oil Services ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIH#NYSE">OIH</a>).
Price Action: BKR shares are up 0.39% at $46.36 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43427872" target="_blank" rel="noreferrer noopener">Dow Dips Over 300 Points As Trump Imposes Tariffs On Canada, Mexico, And China: Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>
Image via Shutterstock.

Equities

Large Cap

Contracts

iShares Dow Jones US Oil Equipment & Services Index Fund

Baker Hughes Lands ExxonMobil Guyana Deal, Partners With Hanwha On Ammonia Turbines

Keybanc analyst Bradley Thomas maintains Tempur Sealy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPX#NYSE">TPX</a>) with a Overweight and raises the price target from $66 to $70.

Keybanc Maintains Overweight on Tempur Sealy Intl, Raises Price Target to $70

Keybanc analyst Paul Knight maintains Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) with a Overweight and raises the price target from $132 to $145.

RVTY

Keybanc Maintains Overweight on Revvity, Raises Price Target to $145

Keybanc analyst Steve Barger maintains RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) with a Overweight and raises the price target from $375 to $395.

Keybanc Maintains Overweight on RBC Bearings, Raises Price Target to $395

Unusual Machines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#NYSE">UMAC</a>) has announced the signing of a binding agreement to acquire of Aloft Technologies, Inc. (<a href="https://pr.report/6pai">https://www.aloft.ai/</a>), the leading FAA-approved provider of unmanned aerial system (UAS) services to enterprise, public safety, and government customers. The acquisition is almost all in stock, valued at $14.5M.
The proposed acquisition brings together companies that share commitment to strengthening the U.S. drone industry. Aloft Technologies has long been recognized as the leader in the drone fleet and airspace management sector, powering more than 70% of all FAA-approved Low Altitude Authorization and Notification Capability (LAANC) airspace authorizations in the United States. Aloft has provided more than more than 1.6 million authorizations in total, with 400,000 authorizations provided in 2024.
Aloft has been able to leverage the data collected through millions of safe flights and airspace interactions to launch <a href="https://pr.report/6paj">Air Boss</a>, their new real-time UAS air traffic management (UTM) software. With the FAA <a href="https://pr.report/6pak">forecasting</a> more than 3 million drones in the airspace by 2028, outnumbering traditional aircraft more than 10-to-1, the coordination and integration of all aircraft is critical to national security and the national economy.
The closing of the acquisition is contingent on satisfaction of customary closing conditions by the parties including Aloft obtaining stockholder approval, the delivery by Aloft of its audited financials acceptable to Unusual Machines, the receipt of certain third party consents and the holders of no more than 10% of Aloft common stock have asserted appraisal rights.

UMAC

Unusual Machines Enters Into Definite Agreement To Acquire Drone Software Company Aloft Technologies; The Acquisition Is Almost All In Stock, Valued At $14.5M

Keybanc analyst Aleksey Yefremov maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Overweight and lowers the price target from $50 to $40.

Keybanc Maintains Overweight on Olin, Lowers Price Target to $40

Buybacks

Axis Capital Enters $200M Stock Repurchase Agreement

LICY

LI-Cycle Further Expands Commercial Footprint In EU With Additional Exclusive Recycling Partnership For Its Germany Spoke

Keybanc analyst Tim Rezvan maintains Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) with a Overweight and lowers the price target from $50 to $37.

Keybanc Maintains Overweight on Murphy Oil, Lowers Price Target to $37

Macro Economic Events

Global

Economics

OPEC+ Discussing Changing List Of Secondary Sources It Uses To Monitor Members' Oil Output; OPEC+ Considers Proposal To Remove U.S. Government's EIA As One Of Its Secondary Sources, Sources Say

Barclays analyst Ramsey El-Assal maintains Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) with a Overweight and raises the price target from $23 to $28.

RELY

Barclays Maintains Overweight on Remitly Global, Raises Price Target to $28

Warning: GNPX is at high risk of performing badly

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Genprex (GNPX) has entered into a Sponsored Research Agreement – SRA – with the University of Michigan Rogel Cancer Center to study TUSC2, the tumo...

Genprex signs two lung cancer research agreements

Genprex (GNPX) announced that its research collaborators at Meharry Medical College will present a poster detailing positive preclinical data from ...

Genprex to present positive preclinical data from Reqorsa Gene Therapy study

Genprex (GNPX) announced it has entered into an exclusive license agreement with the University of Michigan, granting Genprex a worldwide, exclusiv...

Genprex signs exclusive license agreement with University of Michigan

Genprex (GNPX) announced that it has completed the Phase 1 dose escalation portion of the Acclaim-3 clinical trial of Reqorsa Gene Therapy in combi...

Genprex receives Safety Review Committee approval to advance Acclaim-3 trial

Genprex (GNPX) announced that the first patient has been enrolled and dosed in the Phase 2 expansion portion of the company's Acclaim-3 clinical st...

Genprex announces first patient dosed with Regorsa in Phase 2 lung cancer study

AKBA

ALLK

APVO

AVXL

CNSP

CRMD

CRVS

CYCC

DBVT

ELAB

GALT

GNPX

IMUX

MBIO

NBIX

ONCT

SGMO

SYRS

VRNA

Screenshot 2023-07-10 at 5.56.06 PM

Biotech

General

Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

Press Releases

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Cardiol Therapeutics' (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…

Small Cap

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Penny Stocks

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Genprex to Participate in 2024 BIO Europe Conference

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Comments

Genprex

Noticias

Últimas noticias sobre Genprex (NASDAQ:GNPX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL